Hot Topics Banner

What the FDA Relabeling of Abacavir Means for You and Your Patients


Receive notification when new Hot Topics are published:

November 2008

View the presentation

An FDA safety alert reported studies linking potentially fatal hypersensitivity reactions with abacavir, an HIV-antiretroviral medication, to a specific HLA-B allele (HLA-B*5701). Testing patients for this allele, prior to receiving abacavir, is now recommended. Dr. O’Kane and Dr. Yao discuss what this means for you and your patients.


Print Options

Forward to a Colleague

Share this presentation.

If you have questions, email .